Cardiovascular properties of yangambin, a lignan isolated from Brazilian plants

Cardiovascular Drug Reviews

Volumn 19, Issue 4, 2001, Pages 313-328

  Tibiriçá, Eduardo ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Anaphylaxis; Endotoxic shock; Lignans; Ocotea duckei; PAF; PAF antagonist; Platelet Activating Factor; Yangambin

Indexed keywords

2 O ETHYL 1 O HEXADECYL 3 O (7 THIAZOLIOHEPTYL)GLYCEROL MESYLATE; ACETYLCHOLINE; APAFANT; BRADYKININ; CARDIOVASCULAR AGENT; CATECHOLAMINE; FOROPAFANT; GINKGOLIDE B; HISTAMINE; LIGNAN DERIVATIVE; LIPOPOLYSACCHARIDE; PHOSPHORYLCHOLINE; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; YANGAMBIN;

ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAZIL; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG ISOLATION; DRUG RECEPTOR BINDING; NONHUMAN; PLANT; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

EID: 0035723931     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00073.x     Document Type: Review

References (83)

1. Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock
2. Platelet activating factor and its role in trauma, shock, and sepsis
3. Biological and clinical properties of podophyllotoxin and other lignans
4. Rat heart anaphylaxis: Influence of mediator antagonists
5. Natural plant chemicals: Sources of industrial and medicinal materials
6. Ocotea duckei: Exceptional source of yangambin and other furofuran lignans
7. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE basophils and a platelet-activating factor
8. Anaphylaxis
9. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies sepsis
10. Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents
11. Is there a ease for PAF antagonists in the treatment of ischemic states?
12. BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba L.
13. Perspectives in platelet-activating factor research
14. Involvement of platelet-activating factor in the modulation of vascular tone in the isolated perfused rabbit kidney
15. Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: Present status
16. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor
17. Yangambin: A new naturally-occurring platelet-activating factor receptor antagonist: In vivo pharmacological studies
18. Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: In vitro pharmacological studies
19. Pharmacological profile of epiyangambin: A furofuran lignan with PAF antagonist activity
20. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin treated rats
21. Neolignans from Piper futokadsurae
22. Inhibition of low density lipoprotein oxidation by tetrahydrofurofuran lignans from Forsythia suspensa and Magnolia coco
23. Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis
24. Human anaphylaxis
25. Lignans and other non-alkaloidal constituents from Rollinea mucosa
26. Multiple organ failure. Pathophysiology and potential future therapy
27. Inhibition of adenosine 3′,5′-cyclic monophosphate phosphodiesterase by lignan glucosides of Eucommia bark
28. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group
29. (+)-Pinoresinol/(+)-lariciresinol reductase from Forsythia intermedia. Protein purification, cDNA cloning, heterologous expression and comparison to isoflavone reductase
30. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone
31. Platelet-activating factor and cardiac diseases: Therapeutic potential for PAF inhibitors
32. Lignans from leaves, seedlings and micropropagated plants of Rollinia mucosa (JACQ.) Baill. - Annonaceae
33. The causal role of PAF and leukotrienes in acute cardiac allograft rejection in rats
34. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor
35. Cardiovascular activity of naturally occuring lignans
36. Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock
37. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans
38. Chemical studies on medicinal Myristicaceae from Amazonia
39. Potential utilization of Brazilian wood extractives
40. 3H]SR 27417, on guinea-pig tracheal epithelial cells
41. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin
42. Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice
43. Platelet-activating factor type activity in plasma from patients with septicemia and other diseases
44. PAF-receptors antagonists
45. A novel class of non-peptide antagonists isolated from the medicinal herb Phyllanthus niruri
46. Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes
47. Synthesis of PAF-acether and blood volume changes in gram-negative sepsis
48. Platelet-activating factor receptor
49. Yangambin, a lignan obtained from Ocotea duckei, differentiates putative PAF receptor subtypes in the gastrointestinal tract of rats
50. The effect of prednisolone, thromboxane, and platelet-activating factor receptor antagonists on lymphocyte and platelet migration in experimental cardiac transplantation
51. Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy
52. Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea-pigs
53. Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion
54. Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes
55. 2+ channel antagonistic compound from the methanol extract
56. Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus
57. Acetyl glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig
58. Sepsis and multiple organ dysfunction syndrome: A clinical-mechanistic overview
59. Effects of the PAF antagonist WEB 2086 on PAF-induced physiologic alterations and on IgE anaphylaxis in the rabbit
60. The antiviral action of lignans
61. Lignans A review
62. Antihypertensive effect of sesamin. I. Protection against deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy
63. Effects of sesamin on altered vascular reactivity in aortic rings of deoxycorticosterone acetate-salt-induced hypertensive rat
64. Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertension in stroke-prone spontaneously hypertensive rats
65. Lignans from Rollinia species
66. Further lignans from Ocotea duckei
67. Platelet-activating factor antagonists in experimental shock
68. Inhibitors of cyclic AMP phosphodiesterase in medicinal plants
69. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock J
70. Lignans with platelet-activating factor antagonist activity from Magnolia biondii
71. Study of the effector mechanism involved in the production of haemorrhagic necrosis of the small intestine in rat passive anaphylaxis
72. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist
73. Protective effects of yangambin, a natural platelet-activating factor (PAF) receptor antagonist - On the anaphylactic shock in rats
74. Anaphylaxis
75. Anti-allergic properties of the natural PAF antagonist yangambin
76. Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart
77. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors
78. A lethal role of platelet-activating factor in anaphylactic shock in mice
79. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in mice
80. Antagonistic effect of yangambin on platelet-activating factor (PAF)-induced cardiovascular collapse
81. Possible involvement ofplatelet activating factor in anaphylaxis of passively sensitised, isolated guinea pig hearts
82. PAF-acether today-relevance for acute experimental anaphylaxis
83. Myocardial depression characterizes the fatal course of septic shock